Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

Ricks said reshoring manufacturing capacity for older essential medicines is "a valid thing," adding that Eli Lilly is "happy ...

The nonstop route between Indianapolis International Airport and Dublin, Ireland, offers travelers a direct line to one of ...

As President Trump prepares to announce pharmaceutical tariffs, he has one country, in particular, in his sights: Ireland.

The successful trial of a daily weight-loss pill has been hailed as a “landmark moment” in the fight against obesity, with ...

Shares of Eli Lilly fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...